Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
News Today:
COLORADO SPRINGS, Colo., Jun 28, 2010 -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, reports an important milestone for the continued validation of medical cannabis, as UK-based GW Pharmaceuticals (http://gwpharm.com/) receives $15 million milestone payment from Bayer. This payment to GW is based on the UK Government's approval of the "First Prescription Cannabis Medicine", GW Pharmaceuticals Sativex(R), an "Oromucosal Spray" tincture for the treatment of spasticity due to Multiple Sclerosis (MS). Analysts at Piper Jaffray forecast that peak sales could reach $180 million in Europe and Canada combined. Presently, GW has a market capitalization of over $260 million.
Richard Cowan, Cannabis Science CFO noted, "Bayer's $15 million 'milestone payment' to GW clearly puts the world on notice that pharmaceutical cannabis is now 'mainstream'. Previously, the US FDA granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain is currently ongoing. GW has also received an 18 million dollar licensing fee from Otsuka for the US rights, and they also received millions more from licensing fees from Almiral of Spain for the European rights outside of the UK. The licensees also pay for the work necessary for regulatory approval. Clearly, Big Pharma recognizes the explosive growth this industry is experiencing and does not want to be left behind. Obviously, licensing of products and territories -- which is common for new biotech companies -- suggests another important way Cannabis Science can move forward with its financing objectives."
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, said, "The UK Government's approval of Sativex(R) is long overdue. MS patients in the UK and around the world have long used cannabis to get relief from pain and spasticity. We hope, given this recognition of the medical value of cannabis, that the UK government will stop arresting patients who use the plant to deal with their pain and suffering, whatever their medical problems may be. Also, we think this approval should lead to faster regulatory action in the future for medicines derived from whole plant extracts from cannabis. Given the millennia of use that proves the safety of cannabis, and its widespread medical use by millions of people for a great variety of problems today, we hope that the approval of Sativex(R) will lead to the fast-tracking of other whole cannabis extracts by the regulatory authorities."
DISCLAIMER:
Flatrader is not responsible for any loss (or profit) associated with stocks mentioned on this site. Under no circumstances will Flatrader be held liable for losses incurred due to information presented anywhere on the site. Please do your own research before establishing an equity position in a company. Not all stocks mentioned on this site are suitable for your investment needs. Carefully evaluate your own risk tolerances
No comments:
Post a Comment